Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma (Rambro2)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05980000 |
|
Recruitment Status :
Recruiting
First Posted : August 7, 2023
Last Update Posted : January 30, 2024
|
Sponsor:
Washington University School of Medicine
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Washington University School of Medicine
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | April 30, 2028 |
| Estimated Study Completion Date : | April 30, 2031 |